File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Meta-analysis of the P300 and P50 waveforms in schizophrenia

TitleMeta-analysis of the P300 and P50 waveforms in schizophrenia
Authors
KeywordsBiological marker
Endophenotype
Event related potentials
Meta-analysis
P300
P50
Schizophrenia
Issue Date2004
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schres
Citation
Schizophrenia Research, 2004, v. 70 n. 2-3, p. 315-329 How to Cite?
AbstractObjective: To determine whether patients with schizophrenia have abnormalities in the P300 and P50 waves and to quantify the magnitude of any differences from controls. Method: We conducted a systematic search for articles published between January 1994 and August 2003 that reported P50 or P300 measures in schizophrenic patients and controls. Metaregression analyses were performed using a random effects model. The pooled standardised effect size (PSES) was calculated as the difference between the means of the two groups divided by the common standard deviation. Results: We identified 46 studies suitable for analysis of P300 measures, including 1443 patients and 1251 controls. There were 20 P50 studies including 421 patients and 401 controls. The PSES for the P300 amplitude was 0.85 (95% CI: 0.65 to 1.05; p<0.001), and for the P300 latency was -0.57 (95% CI: -0.75 to -0.38; p<0.001). The PSES of the P50 ratio was -1.56 (95% CI: -2.05 to -1.06; p<0.001). There were no significant differences between patients and controls in P50 latency. Across-study variations in filters, task difficulty, antipsychotic medication and duration of illness did not influence the PSES significantly. Conclusions: This meta-analysis confirms the existence of ERP deficits in schizophrenia. The magnitude of these deficits is similar to the most robust findings reported in neuroimaging and neuropsychology in schizophrenia. © 2004 Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/175969
ISSN
2023 Impact Factor: 3.6
2023 SCImago Journal Rankings: 1.374
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorBramon, Een_US
dc.contributor.authorRabeHesketh, Sen_US
dc.contributor.authorSham, Pen_US
dc.contributor.authorMurray, RMen_US
dc.contributor.authorFrangou, Sen_US
dc.date.accessioned2012-11-26T09:03:07Z-
dc.date.available2012-11-26T09:03:07Z-
dc.date.issued2004en_US
dc.identifier.citationSchizophrenia Research, 2004, v. 70 n. 2-3, p. 315-329en_US
dc.identifier.issn0920-9964en_US
dc.identifier.urihttp://hdl.handle.net/10722/175969-
dc.description.abstractObjective: To determine whether patients with schizophrenia have abnormalities in the P300 and P50 waves and to quantify the magnitude of any differences from controls. Method: We conducted a systematic search for articles published between January 1994 and August 2003 that reported P50 or P300 measures in schizophrenic patients and controls. Metaregression analyses were performed using a random effects model. The pooled standardised effect size (PSES) was calculated as the difference between the means of the two groups divided by the common standard deviation. Results: We identified 46 studies suitable for analysis of P300 measures, including 1443 patients and 1251 controls. There were 20 P50 studies including 421 patients and 401 controls. The PSES for the P300 amplitude was 0.85 (95% CI: 0.65 to 1.05; p<0.001), and for the P300 latency was -0.57 (95% CI: -0.75 to -0.38; p<0.001). The PSES of the P50 ratio was -1.56 (95% CI: -2.05 to -1.06; p<0.001). There were no significant differences between patients and controls in P50 latency. Across-study variations in filters, task difficulty, antipsychotic medication and duration of illness did not influence the PSES significantly. Conclusions: This meta-analysis confirms the existence of ERP deficits in schizophrenia. The magnitude of these deficits is similar to the most robust findings reported in neuroimaging and neuropsychology in schizophrenia. © 2004 Elsevier B.V. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schresen_US
dc.relation.ispartofSchizophrenia Researchen_US
dc.subjectBiological marker-
dc.subjectEndophenotype-
dc.subjectEvent related potentials-
dc.subjectMeta-analysis-
dc.subjectP300-
dc.subjectP50-
dc.subjectSchizophrenia-
dc.subject.meshAntipsychotic Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshBrain - Drug Effects - Physiopathologyen_US
dc.subject.meshEvent-Related Potentials, P300 - Drug Effects - Physiologyen_US
dc.subject.meshEvoked Potentials - Drug Effects - Physiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshSchizophrenia - Drug Therapy - Physiopathologyen_US
dc.titleMeta-analysis of the P300 and P50 waveforms in schizophreniaen_US
dc.typeArticleen_US
dc.identifier.emailSham, P: pcsham@hku.hken_US
dc.identifier.authoritySham, P=rp00459en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.schres.2004.01.004en_US
dc.identifier.pmid15329307-
dc.identifier.scopuseid_2-s2.0-4344698417en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-4344698417&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume70en_US
dc.identifier.issue2-3en_US
dc.identifier.spage315en_US
dc.identifier.epage329en_US
dc.identifier.isiWOS:000223809600016-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridBramon, E=8089378900en_US
dc.identifier.scopusauthoridRabeHesketh, S=7003779088en_US
dc.identifier.scopusauthoridSham, P=34573429300en_US
dc.identifier.scopusauthoridMurray, RM=35406239400en_US
dc.identifier.scopusauthoridFrangou, S=7004549374en_US
dc.identifier.citeulike2302088-
dc.identifier.issnl0920-9964-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats